| Type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founder(s) | Jacques Servier |
| Headquarters | Neuilly-sur-Seine, France |
| Products | Coversyl |
| Revenue | €3.5 billion |
| Employees | 20,000 |
| Website | www.servier.com |
Servier Laboratories is a privately owned French pharmaceutical company that specialises in medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression.[1] The consolidated turnover for the 2005/2006 financial year was €3.5 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 140 countries, achieving 82% of its sales outside France.[1] The annual sales of its ACE inhibitor, Coversyl (perindopril), in 2006 and 2007 exceeded 1 billion US dollars, making it Servier's highest-selling product.
The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 20,000 employees worldwide. The company's production sites produced 670 million drug boxes in 2006.[1]
The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[2] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[3]
Contents |
Notable products:
Other products:
Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[5][6] Further investigations found that many previous safety alerts on that drug had been either missed or hushed down, possibly through improper influence of the company.[7]
As well as internal research and development activities, Servier undertakes publicly-funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.[8][9] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[10]